Podcast by Dr. Chadi Nabhan
The Caris Molecular Minute Podcast Series is an outstanding resource for anyone looking to gain a thorough and up-to-date understanding of cancer. Hosted by Dr. Nabhan and his guests, this podcast consistently delivers valuable insights and information in the field of precision medicine. With its helpful and powerful content, it serves as a comprehensive guide to navigating the world of cancer research and treatment.
One of the best aspects of The Caris Molecular Minute Podcast Series is its commitment to providing professional and accurate knowledge on cancer. The hosts and guests are experts in their respective fields, ensuring that listeners receive information that is reliable, well-researched, and up-to-date. This level of expertise instills confidence in the podcast's content, making it a valuable resource for both medical professionals and individuals seeking to expand their knowledge on this complex disease.
Another standout aspect of this podcast is its ability to cover a wide range of topics within the field of precision medicine. Dr. Nabhan and his guests tackle various subjects related to cancer research, diagnostics, treatment options, emerging technologies, patient care, and more. This diverse array of topics ensures that each episode brings something new and insightful to listeners. Whether you're interested in learning about breakthroughs in targeted therapies or exploring the impact of genomics on cancer treatment, there is something for everyone in this podcast.
While there are many positives to highlight about The Caris Molecular Minute Podcast Series, one possible drawback is that it may be too technical for some listeners who are not familiar with medical terminology or concepts related to precision medicine. Although efforts are made to explain complex ideas in an accessible manner, certain episodes may require prior knowledge or further research to fully grasp the content presented.
In conclusion, The Caris Molecular Minute Podcast Series is an invaluable resource for anyone looking to expand their understanding of cancer through the lens of precision medicine. With its knowledgeable hosts, interesting topics, and commitment to delivering accurate information, this podcast stands out as a reliable source of insight in the fight against cancer. Whether you're a medical professional or an individual seeking to stay informed, this podcast is an excellent choice to further your knowledge and understanding of this challenging disease.
Join host Dr. Chadi Nabhan and special guest Dr. Rachna Schroff for a deep dive into the latest highlights from this year's ASCO-GI meeting. Explore novel oncology research, groundbreaking trials, and the transformative role molecular profiling and liquid biopsies are playing in revitalizing the field of gastrointestinal cancer. Don't miss these essential highlights from this year's meeting. For more information, please visit: www.CarisLifeSciences.com
Uncover the path to equitable clinical trials in the latest Caris Molecular Minute podcast with host Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance and his guest, Dr. Ishwaria Subbiah, Executive Director at Sarah Cannon Research Institute. Together, they explore ways to enhance patient access and enrollment, mitigate disparities, and foster equality in clinical trials. Don't miss this thought-provoking conversation aimed at reshaping the narrative for a more inclusive and impactful future in cancer care and research. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. Ari VanderWalde, Global Head of Clinical Trials at Caris Life Sciences. Join them as they delve into the world of clinical trials, exploring the intricacies of clinical research, providing valuable insights into Caris' contributions, and the accessibility of these transformative opportunities. For more information, please visit: www.CarisLifeSciences.com
Join Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance, in a captivating podcast conversation with special guest Dr. Emil Lou, Associate Professor of Medicine at the University of Minnesota. Delve into the intricate connections between pathogens and cancer, exploring both research breakthroughs and the clinical implications. Gain valuable insights into the current landscape and discover what the future holds for this dynamic intersection of science and medicine. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. David Braxton, Chief of Service for Molecular Pathology at Hoag Hospital in Newport Beach, California. Explore Dr. Braxton's remarkable career as a molecular pathologist and delve into the pivotal role molecular pathologists play in precision oncology, while examining the progressive integration of artificial intelligence within molecular pathology. For more information, please visit: www.CarisLifeSciences.com
Join Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, and Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute, as they delve into the depths of radiation therapy in cancer care. Together they'll unravel the intricacies of this vital treatment option, covering its mechanisms, innovations, and the pivotal role it plays in the journey towards effective oncological treatment for patients. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down with Jeanine Cervoni, Senior Director, Commercial Education at Caris Life Sciences in this latest episode of the Caris Molecular Minute podcast series. Join them in this empowering podcast as she shares the strength, resilience and hope that powered her through her personal breast cancer journey. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down with Dr. George Sledge, Executive Vice President and Chief Medical Officer at Caris Life Sciences. Together they delve into his inspiring career as a prominent breast cancer specialist, his passion for this field, and his vision for the future of breast cancer care. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down with Dr. Tina Bhatnagar, Associate Professor, Director of Hematology and Medical Oncology at West Virginia University. Together they discuss disparities research, the types of methodologies used and what can be done to mitigate the disparities seen in practice. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Charu Aggarwal, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at UPENN, and Dr. Balazs Halmos, Director, Thoracic Oncology at Montefiore. Together they discuss adjuvant and neoadjuvant therapy for resected non-small cell lung cancer (NSCLC). Topics discussed will include current treatment options, how treatment decision are made, and when treatment should be given. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Soma Sengupta, the Harold C. Schott Endowed Brain Tumor Molecular Therapeutics Chair and Associate Professor of Clinical at the University of Cincinnati. Together they explore the myriad of challenges in accurately diagnosing this aggressive brain tumor while examining the latest advancements in frontline treatment strategies. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephen Liu, Associate Professor of Medicine at Georgetown University and Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Together they discuss the updated results of the ADAURA Trial presented at this year's ASCO meeting which demonstrated the overall survival benefit when adding osimertinib versus placebo in patients with completely resected stage IB-IIIA NSCLC, with/without adjuvant chemotherapy. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Giselle Sholler, Director of the Isabella Santos Rare and Solid Tumor Program at the Levine Children's Hospital, and Professor of Pediatrics and Principle Investigator of the Sholler Pediatric Oncology Research Laboratory. Together they discuss trends in managing pediatric hematologic cancers and how molecular profiling and genomic profiling intersect with clinical care. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. JJ Gao, VP, Translational Informatics at Caris Life Sciences. Together they discuss his role in leading the Translational Informatics team at Caris Life Sciences and how artificial intelligence and bioinformatics are utilized to synthesize data to support cancer research and improve the outcomes of patients. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. R. Donald Harvey, Professor Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of Winship Cancer Institute's Phase I Clinical Trials Unit. Together they discuss the role of the pharmacist in pharmacovigilance and pharmacoadherence, and how we can ensure that patients are being properly educated and compliant with the new products being approved each day. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Nathan Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program and Vice Chair of Clinical Research for the Taussig Cancer Institute. Together they discuss the methodology and results of a recent JCO paper for which Dr. Pennell was a senior author: Modeling Costs and Life-Years Gained by Population-Wide NGS or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the US. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Premal Thaker, Professor of Obstetrics and Gynecology, and Director of Gynecological Oncology Clinical Research at the Washington University School of Medicine in Saint Louis. Together they discuss the advances in gynecological malignancies in the era of precision medicine, how they have impacted her practice, and how HRD (homologous recombination deficiency) is changing the way we treat patients today. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Kristen Spencer, Assistant Professor, Department of Medicine and Director, Phase I Developmental Therapeutics Program at NYU Langone Perlmutter Cancer Center to discuss the latest findings and top abstracts presented at this year's ASCO GI meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down for an intimate discussion with Tiffany McConathy, nurse practitioner at Genesis Cancer and Blood Institute. Tiffany shares her family's personal hardship of learning their eleven-month-old daughter Nora was diagnosed with embryonal tumor with multilayer rosettes (EMTR), a rare and untreatable form of pediatric brain cancer. Together, Chadi and Tiffany discuss Nora's initial diagnosis, patient journey and the critical importance of dedicating research and resources to rare diseases such as EMTR. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Bishoy Faltas, Assistant Professor of Medicine at Weill Cornell Medical College. Together they discuss bladder cancer, the evolution of the disease, and the latest research being conducted to improve the outcomes of patients. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Soo Park, Assistant Professor in the Division of Hematology-Oncology at UC San Diego Health. Together they discuss how precision medicine and molecular profiling have shaped the way we care for patients with cutaneous cancers. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Advance Practice Providers Kathryn Simon and Sarah Wyman from the Winship Cancer Institute at Emory University. Together they discuss the impact and contributions Advance Practice Providers make to oncology care in the era of precision medicine. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Milan Radovich, Senior Vice President and Chief Precision Medicine Officer at Caris Life Sciences. Together they discuss the future of precision medicine, how precision oncology is evolving into the earlier stages of disease, and the paradigm shifts to look for in the overall survival of cancer. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Emil Lou, Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota. Together they discuss the challenges in gastrointestinal cancer and how liquid biopsies are applied within these malignancies. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Elisabeth Heath, Professor of Oncology and Associate Center Director, Translational Sciences, at the Karmanos Cancer Institute. Together they discuss the advances and future of liquid biopsies and their clinical utilization within genitourinary cancers. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephen Liu, Associate Professor of Medicine at Georgetown University and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together they discuss liquid biopsies and their utilization in thoracic malignancies. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. David Spetzler, President and Chief Scientific Officer at Caris Life Sciences®, to discuss the latest advances in liquid biopsies, the clinical utility of these offerings, and how precision oncology is leveraging this new source of molecular information to improve patient outcomes. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Jimmy Hwang, Chief, GI Medical Oncologist at the Levine Cancer Institute. Dr. Hwang recently contributed to a JCO publication titled, “Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.” Together, Dr. Nabhan and Dr. Hwang discuss the recommendations made in this article and the impact genomic testing can have on patient outcomes. To access this article, please visit: https://ascopubs.org/doi/full/10.1200/JCO.21.02767 For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Jamie Holloway, Area Vice President, Molecular Science Liaison at Caris Life Sciences. Together, they take a closer look at the Caris Report and explain how its results aid oncologists in personalizing cancer therapies for their patients. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Patricia Pittman, oncologic pathologist and neuropathologist at Caris Life Sciences, to discuss the latest in neuropathology. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Tian Zhang, Associate Professor at UT Southwestern Medical Center, to discuss the latest findings and top abstracts presented at this year's ASCO GU meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Ben Weinberg, Associate Professor of Medicine at Georgetown University, to discuss the latest findings and top abstracts presented at this year's ASCO GI meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief of Radiation Oncology at Rutgers Cancer Institute. Together they discuss radiation oncology and its role in cancer care. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with David Dubin, a 3-time colon cancer survivor, kidney cancer survivor, and third generation Lynch Syndrome carrier. Together they discuss his journey as a patient and how his foundation, www.Aliveandkickn.org, is helping to improve the lives of individuals and families affected by Lynch Syndrome. For more information, please visit: www.CarisLifeSciences.com
In recognition of Breast Cancer Awareness Month, Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephanie Graff, Director of Breast Oncology at the Lifespan Cancer Institute at Brown University. Together they discuss the latest advances in breast cancer. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Igor Astsaturov, Co-director of the Pancreatic Institute at Fox Chase Cancer Center and Chairman of the Caris Molecular Tumor Board. Together they discuss molecular tumor boards and how they are utilized at Caris and other academic sites. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Elisabeth Heath, Associate Center Director of Translational Sciences at Karmanos Cancer Institute. Together they discuss the latest findings and top abstracts in GU oncology that were presented at this year's ASCO meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Charu Aggarwal, the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania Perelman School of Medicine. Together they discuss the latest findings and top abstracts in thoracic oncology that were presented at this year's ASCO meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Muhammad Shaalan Beg, Director for Gastrointestinal (GI) Medical Oncology at UT Southwestern to discuss the latest findings and top abstracts in GI that were presented at this year's ASCO meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Trisha Wise-Draper, Associate Professor of Medicine in the Division of Hematology/Oncology at the University of Cincinnati. Together they discuss the latest advances in head and neck cancers as well as findings from this year's ASCO meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Neeraj Agarwal, Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute. Together they discuss genomic profiling and sequencing in GU malignancies. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Sonikpreet Aulakh, Assistant Professor of Medicine in translational neuro-oncology from West Virginia University, to discuss the impact of precision oncology on the treatment of brain tumors. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. Together they discuss the latest treatments in neuroendocrine tumors (NETs) and the elements that allow us to understand the prognosis on both molecular and histopathology levels.
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Olga Weinberg who is a hematopathologist and Director of Fellowship Education at UT Southwestern Medical Center. Together they discuss pediatric oncology and the applicability of NGS to these types of cancers. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Don Dizon, Director of Women's Cancers at Brown University's Lifespan Cancer Institute. Together they discuss precision oncology and the impact of genomic profiling and sequencing in the management of women with various gynecological malignancies. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Paolo Ascierto, Director of the Unit of Melanoma and the Oncological Immunotherapy and Innovative Therapies Director at the National Tumor Institute “Fondazione G. Pascale”, in Naples, Italy. As the founder of both the Melanoma Bridge Meeting and the Immunotherapy Bridge Meeting, Dr. Ascierto shares outcomes from both meetings as well as insights into the latest treatments in both disease states. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Rana McKay, Associate Professor of Medicine from the University of California San Diego Health to discuss the latest findings and top abstracts presented at this year's virtual ASCO GU meeting. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Matthew Oberley, Executive Medical Director at Caris Life Sciences, to discuss how genomic profiling and AI are helping clinicians determine tumor origin for cancers of unknown primary (CUP) cases. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Emil Lou, Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota, to discuss the recent advances and future within GI oncology. For more information, please visit: www.CarisLifeSciences.com
Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. John Marshall, Chief, Division of Hematology/Oncology at Georgetown University, and Dr. Tony Shields, Associate Center Director, Clinical Sciences at Karmanos Cancer Center Institute. Both are co-authors on the December 8, 2020 paper: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer found in Clinical Cancer Research, a journal of the American Association for Cancer Research. In this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa. For more information, please visit: www.CarisLifeSciences.com/MI-FOLFOXai/
© 2020-2025 Ivy Podcast Discovery LLC
